Request Trial
shutterstock_1644424099_angellodeco
angellodeco / Shutterstock.com
19 March 2020AmericasEdward Pearcey

Fortress offers licences after COVID-19 testing patent backlash

Labrador Diagnostics, a subsidiary of Fortress Investment Group, has offered royalty-free licences to third parties for its patent-protected diagnostics technology, just days after suing US-based health startup BioFire, which is attempting to develop COVID-19 testing kits.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Lupin scores another win in kidney drug dispute
22 May 2026   A US appeals court has handed the generic drugmaker victory in a closely watched dispute over a treatment for a serious inherited kidney condition, dealing a setback to its branded rival.
Americas
Battle over inhaler shape ends badly for Boehringer
21 May 2026   European officials have again sided with Glenmark, concluding that the 3D mark for Boehringer’s HandiHaler device is ineligible for registration.
Americas
Jones Day adds in-house biologics specialist to Boston office
20 May 2026   The firm brings in a former VP at a biotech company, with biologics experience across antibodies, antibody drug-conjugates, peptides and gene and cell therapies.


Editor's picks

Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

Editor's picks

Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

More features

Lupin scores another win in kidney drug dispute
Battle over inhaler shape ends badly for Boehringer
Chinese medtech company fined by UPC over injunction breaches
Healthcare leads sweeping AI partnership in Singapore
Jones Day adds in-house biologics specialist to Boston office
Kirkland & Ellis subject of alleged conflict in trade secrets clash
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
Orrick lands five-member M&A team in Paris